Gastrointestinal cancers presents a pressing challenge marked by unmet medical needs. Stomach, pancreas, colon, bile duct, and liver cancers collectively bear a significant burden, characterized by their high mortality rates and limited treatment alternatives. The complexity of these malignancies demands a new era of innovative therapeutic interventions that can effectively target the intricate molecular pathways driving tumor growth and progression. ​

​

Arbele is steadfast in its mission to bridge this therapeutic gap, pioneering groundbreaking drug development to provide hope and healing to patients grappling with these diseases. Our commitment to advancing scientific understanding and delivering novel solutions underscores our dedication to transforming the landscape of gastrointestinal cancer treatment.​